NYSEAM:PLXBiotechs
Protalix BioTherapeutics (PLX) Valuation in Focus After EMA Setback on Elfabrio Dosing Schedule
Protalix BioTherapeutics (PLX) saw its stock take a hit after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the revised dosing schedule for Elfabrio, developed with Chiesi Group.
See our latest analysis for Protalix BioTherapeutics.
Shares of Protalix BioTherapeutics tumbled 22.5% in a day as the market reacted to the EMA’s negative decision, swiftly erasing gains from earlier momentum. Despite this sharp setback, investors who...